PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 72.2% in December

PolyPid Ltd. (NASDAQ:PYPD) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 63,411 shares, a growth of 72.2% from the November 30th total of 36,815 shares. Based on an average daily volume of 109,414 shares, the short-interest ratio is currently 0.6 days. Approximately 0.5% of the shares of the company are sold short. Approximately 0.5% of the shares of the company are sold short. Based on an average daily volume of 109,414 shares, the short-interest ratio is currently 0.6 days.

Institutional Investors Weigh In On PolyPid

A number of large investors have recently bought and sold shares of PYPD. BNP Paribas Financial Markets raised its holdings in shares of PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares during the last quarter. Lumbard & Kellner LLC purchased a new stake in PolyPid during the 2nd quarter worth about $135,000. Finally, AIGH Capital Management LLC raised its stake in PolyPid by 27.0% in the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock valued at $4,215,000 after purchasing an additional 253,727 shares during the last quarter. Institutional investors and hedge funds own 26.47% of the company’s stock.

PolyPid Stock Performance

NASDAQ PYPD traded up $0.05 during trading hours on Friday, reaching $4.07. The company’s stock had a trading volume of 29,203 shares, compared to its average volume of 84,264. The company’s 50-day moving average is $3.77 and its two-hundred day moving average is $3.57. PolyPid has a fifty-two week low of $2.30 and a fifty-two week high of $4.10. The stock has a market cap of $64.70 million, a PE ratio of -1.37 and a beta of 1.49.

PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.17. Equities analysts expect that PolyPid will post -1.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Roth Capital decreased their price target on PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Wall Street Zen upgraded shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PolyPid in a research note on Wednesday, October 8th. Finally, Citigroup reiterated a “market outperform” rating on shares of PolyPid in a report on Monday, December 1st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, PolyPid has an average rating of “Moderate Buy” and a consensus price target of $12.40.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.